Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients

被引：0
|
作者：
Hugh Wiltshire
Sarapee Hirankarn
Colm Farrell
Carlos Paya
Mark D. Pescovitz
Atul Humar
Edward Dominguez
Kenneth Washburn
Emily Blumberg
Barbara Alexander
Richard Freeman
Nigel Heaton
机构：
[1] Roche Products Ltd,Departments of Surgery/Microbiology/Immunology
[2] GloboMax — a division of ICON plc,undefined
[3] Mayo Clinic,undefined
[4] Indiana University,undefined
[5] Toronto General Hospital,undefined
[6] University of Nebraska Medical Center,undefined
[7] University of Texas Health Science Center,undefined
[8] Hospital of the University of Pennsylvania,undefined
[9] Duke University Medical Center,undefined
[10] New England Medical Center,undefined
[11] King’s College,undefined
来源：
Clinical Pharmacokinetics | 2005年 / 44卷
关键词：
Ganciclovir; Pharmacokinetic Model; Ethylene Diamine Tetraacetic Acid; Ethylene Diamine Tetraacetic Acid; Kidney Transplant Recipient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：495 / 507
页数：12
相关论文
共 50 条
  • [1] Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients
    Wiltshire, H
    Hirankarn, S
    Farrell, C
    Paya, C
    Pescovitz, MD
    Humar, A
    Dominguez, E
    Washburn, K
    Blumberg, E
    Alexander, B
    Freeman, R
    Heaton, N
    CLINICAL PHARMACOKINETICS, 2005, 44 (05) : 495 - 507
  • [2] Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients
    Wiltshire, H
    Paya, CV
    Pescovitz, MD
    Humar, A
    Dominguez, E
    Washburn, K
    Blumberg, E
    Alexander, B
    Freeman, R
    Heaton, N
    Zuideveld, KP
    TRANSPLANTATION, 2005, 79 (11) : 1477 - 1483
  • [3] Comparison of valganciclovir and oral ganciclovir for cytomegalovirus prophylaxis in solid organ transplant recipients.
    Kraman, AA
    Hardwick, LL
    Filo, RS
    Govani, MV
    Milgrom, ML
    Tector, AJ
    Pescovitz, MD
    PHARMACOTHERAPY, 2002, 22 (10): : 1370 - 1370
  • [4] Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir
    Perrottet, N.
    Csajka, C.
    Pascual, M.
    Manuel, O.
    Lamoth, F.
    Meylan, P.
    Aubert, J. D.
    Venetz, J. P.
    Soccal, P.
    Decosterd, L. A.
    Biollaz, J.
    Buclin, T.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) : 3017 - 3023
  • [5] Population Pharmacokinetics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in Solid Organ Transplant Patients Infected with Cytomegalovirus
    Caldes, A.
    Colom, H.
    Armendariz, Y.
    Garrido, M. J.
    Troconiz, I. F.
    Gil-Vernet, S.
    Lloberas, N.
    Pou, L.
    Peraire, C.
    Grinyo, J. M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) : 4816 - 4824
  • [6] Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir
    Boivin, Guy
    Goyette, Nathalie
    Rollag, Halvor
    Jardine, Alan G.
    Pescovitz, Mark D.
    Asberg, Anders
    Ives, Jane
    Hortmann, Anders
    Humar, Atul
    ANTIVIRAL THERAPY, 2009, 14 (05) : 697 - 704
  • [7] Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
    Asberg, A.
    Humar, A.
    Rollag, H.
    Jardine, A. G.
    Mouas, H.
    Pescovitz, M. D.
    Sgarabotto, D.
    Tuncer, M.
    Noronha, I. L.
    Hartmann, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) : 2106 - 2113
  • [8] A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children
    Lukacova, V.
    Goelzer, P.
    Reddy, M.
    Greig, G.
    Reigner, B.
    Parrott, N.
    AAPS JOURNAL, 2016, 18 (06): : 1453 - 1463
  • [9] A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children
    V. Lukacova
    P. Goelzer
    M. Reddy
    G. Greig
    B. Reigner
    N. Parrott
    The AAPS Journal, 2016, 18 : 1453 - 1463
  • [10] Oral valganciclovir is non-inferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
    Asberg, Anders
    Humar, Atul
    Rollag, Halvor
    Jardine, Alan G.
    Mouas, Houria
    Pescovitz, Mark D.
    Dittmer, Ian
    Montejo, Miguel
    Toz, Huseyin
    Hartmann, Anders
    TRANSPLANT INTERNATIONAL, 2007, 20 : 36 - 36
12345